CA2323237A1 - Methodes ameliorees de radiotherapie - Google Patents

Methodes ameliorees de radiotherapie Download PDF

Info

Publication number
CA2323237A1
CA2323237A1 CA002323237A CA2323237A CA2323237A1 CA 2323237 A1 CA2323237 A1 CA 2323237A1 CA 002323237 A CA002323237 A CA 002323237A CA 2323237 A CA2323237 A CA 2323237A CA 2323237 A1 CA2323237 A1 CA 2323237A1
Authority
CA
Canada
Prior art keywords
analogues
aii
radiation therapy
therapy methods
angiotensin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002323237A
Other languages
English (en)
Other versions
CA2323237C (fr
Inventor
Kathleen E. Rodgers
Gere Dizerega
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA2659664A priority Critical patent/CA2659664C/fr
Publication of CA2323237A1 publication Critical patent/CA2323237A1/fr
Application granted granted Critical
Publication of CA2323237C publication Critical patent/CA2323237C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/14—Angiotensins: Related peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0644—Platelets; Megakaryocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/32—Angiotensins [AT], angiotensinogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002323237A 1998-03-10 1999-03-08 Methodes ameliorees de radiotherapie Expired - Fee Related CA2323237C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2659664A CA2659664C (fr) 1998-03-10 1999-03-08 Methodes ameliorees de radiotherapie

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US7738298P 1998-03-10 1998-03-10
US60/077,382 1998-03-10
US8126298P 1998-04-09 1998-04-09
US60/081,262 1998-04-09
US8367098P 1998-04-30 1998-04-30
US60/083,670 1998-04-30
US9009698P 1998-06-19 1998-06-19
US60/090,096 1998-06-19
US9021698P 1998-06-22 1998-06-22
US60/090,216 1998-06-22
US9995798P 1998-09-11 1998-09-11
US60/099,957 1998-09-11
PCT/US1999/005194 WO1999045945A1 (fr) 1998-03-10 1999-03-08 Methodes ameliorees de radiotherapie

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2659664A Division CA2659664C (fr) 1998-03-10 1999-03-08 Methodes ameliorees de radiotherapie

Publications (2)

Publication Number Publication Date
CA2323237A1 true CA2323237A1 (fr) 1999-09-16
CA2323237C CA2323237C (fr) 2009-05-19

Family

ID=27557165

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2659664A Expired - Fee Related CA2659664C (fr) 1998-03-10 1999-03-08 Methodes ameliorees de radiotherapie
CA002323237A Expired - Fee Related CA2323237C (fr) 1998-03-10 1999-03-08 Methodes ameliorees de radiotherapie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2659664A Expired - Fee Related CA2659664C (fr) 1998-03-10 1999-03-08 Methodes ameliorees de radiotherapie

Country Status (5)

Country Link
EP (1) EP1061937A1 (fr)
JP (1) JP3728400B2 (fr)
AU (1) AU744799B2 (fr)
CA (2) CA2659664C (fr)
WO (1) WO1999045945A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6730775B1 (en) 1999-03-23 2004-05-04 University Of Southern California Methods for limiting scar and adhesion formation
US7338938B2 (en) 1999-05-10 2008-03-04 University Of Southern California Methods for treating a patient undergoing chemotherapy
AU2002308522A1 (en) * 2001-05-01 2002-11-11 University Of Southern California Methods for inhibiting tumor cell proliferation
AU2002257970B2 (en) 2001-05-31 2007-08-02 Vicore Pharma Ab Tricyclic compounds useful as angiotensin II agonists
WO2011120032A1 (fr) * 2010-03-26 2011-09-29 University Of Southern California Méthodes pour traiter des lésions combinées de radiation et thermiques
WO2011127144A1 (fr) 2010-04-06 2011-10-13 Synedgen Inc. Procédés et compositions de traitement de blessures utilisant des composés de chitosane
US20120071397A1 (en) * 2010-08-10 2012-03-22 University Of Southern California Methods for Hematopoietic Stem Cell Transplantation
EP2455388A1 (fr) 2010-11-23 2012-05-23 LanthioPep B.V. Nouveaux agonistes du récepteur 2 (AT2) de type angiotensine et leurs utilisations
US20150050250A1 (en) * 2012-04-05 2015-02-19 University Of Southern California Cell therapy technology to deliver radio-protective peptides
US8557958B1 (en) 2012-06-18 2013-10-15 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of diabetes
CA2883704C (fr) 2012-09-20 2021-09-28 Synedgen, Inc. Procedes pour le traitement ou la prevention de dommages resultant d'un rayonnement, d'un trauma ou d'un choc
US8633158B1 (en) 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
US9333233B2 (en) 2014-02-25 2016-05-10 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke
JP2022542437A (ja) 2019-08-02 2022-10-03 ランティオペプ ベスローテン ヴェンノーツハップ 癌の処置に用いるアンジオテンシン２型（ａｔ２）受容体アゴニスト

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE457055B (sv) * 1986-08-18 1988-11-28 Ferring Ab Topisk straalskyddsgel foer mukosa innehaallande kaerlsammandragande substanser
US5015629A (en) * 1989-06-26 1991-05-14 University Of Southern California Tissue repair
WO1995008565A1 (fr) * 1993-09-24 1995-03-30 The University Of Southern California Utilisation d'analogues d'angiotensine ii pour la reparation tissulaire
WO1997034627A2 (fr) * 1996-03-19 1997-09-25 Societe De Conseils De Recherches Et D'applications Scientifiques S.A. Protection de cellules hematopoietiques durant une chimiotherapie ou une radiotherapie

Also Published As

Publication number Publication date
AU2995799A (en) 1999-09-27
EP1061937A1 (fr) 2000-12-27
CA2659664C (fr) 2013-05-07
JP3728400B2 (ja) 2005-12-21
AU744799B2 (en) 2002-03-07
JP2002506042A (ja) 2002-02-26
WO1999045945A1 (fr) 1999-09-16
CA2323237C (fr) 2009-05-19
CA2659664A1 (fr) 1999-09-16

Similar Documents

Publication Publication Date Title
CA2328871A1 (fr) Procedes permettant d'accelerer la reparation et la croissance des os et des cartilages
CA2323237A1 (fr) Methodes ameliorees de radiotherapie
WO2000053211A3 (fr) Methode de stimulation de la proliferation de myocytes et de la reparation des tissus myocardiques
EP0781136A4 (fr) Composes et procedes de traitement du cancer
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
WO1999040106A3 (fr) Procede pour promouvoir l'erythropoiese
EP0911321A3 (fr) Composés pour le traitement de l'ostéoporose
DE69924715D1 (de) Verwendung von angiotensin analogen zur herstellung eines arzneimittels zur steigerung des ueberlebens der weissen blutzellen und mobilisierung von haematopoietischen stammzellen nach einer chemotherapeutischen behandlung
WO1998058911A3 (fr) Agonistes de prostaglandines
WO2000015247A3 (fr) Traitement du myelome multiple et de la resorption osseuse provoquee par le myelome au moyen d'antagonistes de l'interaction -cam-1/vla-4
WO1999046285A3 (fr) Procede permettant de favoriser la production d'equivalents de tissus vivants
WO1998033813A3 (fr) Procede permettant d'accelerer la guerison de brulures
WO2002092013A3 (fr) Methodes de traitement des maladies du foie et des lesions du foie a l'aide de l'hormone de croissance et de la proteine foxm1b
ATE335496T1 (de) Angiotensin ii und analoga zur begrenzung von narben und adhäsionbildung
MXPA02001204A (es) Compuestos calciliticos.
IL158433A0 (en) Toluene sulfonamide-containing anti-tumor composition and method of use thereof
WO2001043761A3 (fr) Procedes permettant de traiter et d'empecher des lesions des muqueuses
WO2001055176A3 (fr) Procedes d'inhibition de la proliferation des cellules du muscle lisse
WO2002006308A3 (fr) Procedes favorisant la proliferation ou la differenciation des cellules dendritiques
WO2001044270A3 (fr) Procedes permettant de traiter et d'empecher des complications diabetiques
EP0967276A3 (fr) Agent antitumorale comprenant le salmosine
PL336897A1 (en) Novel salts of bpc peptides, pharmaceutic compositions conatining them and method of obtaining such salts
DK0934342T3 (da) Præparat indeholdende chitosan
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
WO1999050671A3 (fr) Proteine toso comme cible de criblage de medicaments

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160308